ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia
- Author(s)
- Hourigan, CS; Beugelink, L; Othman, J; Gui, G; Ivey, A; Dillon, RJ; Thiede, C; Levis, MJ; Dillon, LW; Wei, AH; Tiong, IS; Loo, S; Döhner, K; Arnhardt, I; Kowalik, A; Potter, N; Kim, DDH; Preudhomme, C; Duployez, N; Heuser, M; Valk, PJ;
- Journal Title
- Blood
- Publication Type
- Online publication before print
- Abstract
- FLT3-ITD measurable residual disease (MRD) testing for patients in remission from acute myeloid leukemia (AML) is now recommended by the recently updated clinical standard of care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.
- Department(s)
- Haematology; Pathology
- Publisher's Version
- https://doi.org/10.1182/blood.2026033569
- Open Access at Publisher's Site
https://doi.org/10.1182/blood.2026033569- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-06-23 03:42:06
Last Modified: 2026-06-23 03:42:14